Skip to content

Homepage

Author: Abeona Therapeutics Inc.

Posted Date:

July 1, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Inc.

July 1, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Inc.

June 1, 2026
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Abeona Therapeutics Inc.

May 26, 2026
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update

Abeona Therapeutics Inc.

May 13, 2026
Abeona Therapeutics® Announces Activation of Children’s Hospital of Philadelphia as a New Qualified Treatment Center for ZEVASKYN®

Abeona Therapeutics Inc.

May 11, 2026
Abeona Therapeutics® Announces Date of First Quarter Financial Results

Abeona Therapeutics Inc.

May 4, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Inc.

May 1, 2026
Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

Abeona Therapeutics Inc.

April 7, 2026
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics Inc.

April 6, 2026
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York

Abeona Therapeutics Inc.

April 2, 2026

1 2